ExpertiseUpdated on 30 April 2025

Up- and downstream of gene therapy vectors

Martin Trinker

Director Business Development & Fundraising at acib GmbH

Graz, Austria

About

Gene therapy vectors, such as AAVs, Virus-like particles (VLPs) or exosomes are in high demand, leading to challenging timelines for delivering sufficient amounts in highest quality. acib has both, the facilities and the expertise to provide interested parties with fast and efficient production processes.

The critical and cost driving step in the development of gene therapy vectors, is the production process which requires not only a deep understanding of the process mechanisms, but also high-throughput analytical tools, and state-of-the-art up- and downstream processing equipment. acib has everything you need and in addition to expertise in viral vectors and particle expression in cell culture, also extensive know-how in purification processes.

acib’s upstream processing infrastructure consists of bioreactor systems configured for cell culture (mammalian or insect cells) and virus applications up to 10L and a parallel multibioreactor system. Both can be combined with an alternating tangential flow system to deliver high cell concentrations and process intensification. For downstream processing we provide a pilot-scale continuous ultracentrifuge with a fluid handling sys‐ tem and a preparative chromatography with MALS detector. This equipment is complemented by advanced analytical tools like nanoparticle tracking analysis, microflow cytometer, asymmetric flow field-flow fractionation and analytic HPLC with UV-MALS-DLS-RI detector. All equipment is in a dedicated BSL2 facility.

Similar opportunities